Skip to main content
BJDX
NASDAQ Industrial Applications And Services

Bluejay Q3: $7.4M Cash, Going Concern Reaffirmed, $10-14M Raise Still Needed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.605
Mkt Cap
$2.91M
52W Low
$1.841
52W High
$28
52W Position info
42% above low
Off High info
91% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BJDX sits 42% above its 52-week low of $1.841 on light trading volume (0.1× avg).

Summary

Bluejay's Q3 10-Q shows $7.4 million of cash, a $6.3 million nine-month net loss, and a reaffirmed going concern warning, with $10-14 million of additional capital still needed by the end of fiscal 2027.


Key Events · Earnings and Guidance · BJDX

  • Q3 Net Loss Widens to $6.3M

    Nine-month net loss was $6,255,097 versus $5,418,671 a year earlier, and the quarter alone lost $2,011,843. R&D rose to $3,366,212 from $2,460,304 on SYMON-II trial costs.

  • Cash of $7.4M, Runway to Q2 2027

    Cash and equivalents were $7,379,983 at September 30, 2026 against current liabilities of $1,927,320. Management estimates this funds operations only through the second quarter of 2027.

  • Going Concern and Liquidation Risk

    The filing states substantial doubt about the ability to continue as a going concern and warns that without financing the board could pursue a Chapter 7 liquidation in which shareholders could recoup little or nothing.

  • $10-14M Raise Still Required

    Bluejay expects to need $10.0 million to $14.0 million of additional capital by the end of fiscal 2027 to fund commercialization and a planned 510(k) submission in the first half of 2027.


Analysis · BJDX · Industrial Applications And Services

Bluejay closed September with $7.4 million in cash against $1.9 million of current liabilities, yet the 10-Q reaffirms the going concern warning and states that cash only funds operations through the second quarter of 2027. To reach a 510(k) submission in the first half of 2027, the company still needs $10-14 million, and it warns that failure to raise could force a Chapter 7 liquidation. The nine-month net loss widened to $6.3 million from $5.4 million as R&D spending climbed on the SYMON-II sepsis trial. After the November 3 reverse split cut shares to 1.1 million, the filing flags that a close below $1.00 for 30 straight trading days would put the Nasdaq listing at risk, with no cure period available before the one-year anniversary of the January 2026 split.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BJDX was trading at $2.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.84 to $28.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BJDX - Latest Insights

BJDX
Oct 30, 2026, 10:30 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.4615
Real-time Price: $2.61 info
Change: Reverse Stock Split info
Market Cap: $2.91M info
BJDX
Aug 13, 2026, 7:56 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $2.61 info
Change: Reverse Stock Split info
Market Cap: $2.91M info
BJDX
Aug 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $2.61 info
Change: Reverse Stock Split info
Market Cap: $2.91M info
BJDX
Aug 12, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $2.61 info
Change: Reverse Stock Split info
Market Cap: $2.91M info
BJDX
Jul 22, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $2.61 info
Change: Reverse Stock Split info
Market Cap: $2.91M info